Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus.

PubWeight™: 1.43‹?› | Rank: Top 5%

🔗 View Article (PMC 2993510)

Published in Transplantation on October 15, 2004

Authors

Amadeo Marcos1, Bijan Eghtesad, John J Fung, Paulo Fontes, Kusum Patel, Michael Devera, Wallis Marsh, Timothy Gayowski, Anthony J Demetris, Edward A Gray, Bridget Flynn, Adriana Zeevi, Noriko Murase, Thomas E Starzl

Author Affiliations

1: Thomas E. Starzl Transplantation Institute, Pittsburgh, Pennsylvania, USA.

Articles citing this

Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl (2012) 4.65

Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg (2005) 1.10

Current landscape for T-cell targeting in autoimmunity and transplantation. Immunotherapy (2011) 1.02

Overview of immunosuppression in liver transplantation. World J Gastroenterol (2009) 0.96

Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg (2007) 0.94

The unfinished legacy of liver transplantation: emphasis on immunology. Hepatology (2006) 0.93

Development of tolerogenic strategies in the clinic. Philos Trans R Soc Lond B Biol Sci (2005) 0.86

Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem. World J Gastroenterol (2014) 0.83

Long-term management of immunosuppression after pediatric liver transplantation: is minimization or withdrawal desirable or possible or both? Curr Opin Organ Transplant (2008) 0.83

Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. Transplantation (2006) 0.82

Five-year outcomes with alemtuzumab induction after lung transplantation. J Heart Lung Transplant (2011) 0.82

Pancreatic transplantation at the University of Pittsburgh. Clin Transpl (2004) 0.81

Review on immunosuppression in liver transplantation. World J Hepatol (2015) 0.79

Liver transplantation and hepatitis C. Int J Hepatol (2012) 0.79

Lymphodepletional strategies in transplantation. Cold Spring Harb Perspect Med (2013) 0.78

Prope tolerance with alemtuzumab. Liver Transpl (2005) 0.76

Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now? World J Gastroenterol (2015) 0.75

Prevention of hepatitis C recurrence after liver transplantation: An update. World J Gastrointest Pharmacol Ther (2012) 0.75

Articles cited by this

The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24

Studies on heterologous anti-lymphocyte serum in mice. II. Effect on the immune response. J Immunol (1966) 4.49

Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med (2003) 4.12

Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09

Antigen localization and migration in immunity and tolerance. N Engl J Med (1998) 3.71

EFFECT OF LYMPHOCYTE DEPLETION BY THORACIC DUCT FISTULA AND ADMINISTRATION OF ANTILYMPHOCYTIC SERUM ON THE SURVIVAL OF SKIN HOMOGRAFTS IN RATS. Nature (1963) 3.65

Banff schema for grading liver allograft rejection: an international consensus document. Hepatology (1997) 3.22

Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant (2003) 2.83

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet (1998) 2.26

Transplantation tolerance from a historical perspective. Nat Rev Immunol (2001) 2.04

A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg (2001) 1.73

Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52

Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation (2004) 1.33

Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl (2002) 1.03

Specificity of monoclonal antibody Campath-1. Bone Marrow Transplant (1988) 0.95

Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. Transplantation (2003) 0.93

Real-time monitoring of acute liver-allograft rejection using the Banff schema. Transplantation (2002) 0.91

No tolerance for depletion. Nat Med (2004) 0.82

Articles by these authors

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98

Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31

A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31

Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant (2005) 5.87

Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54

Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09

Production of alpha 1,3-galactosyltransferase-deficient pigs. Science (2002) 3.96

Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant (2007) 3.90

Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18

A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med (2006) 3.16

Generation of cloned transgenic pigs rich in omega-3 fatty acids. Nat Biotechnol (2006) 3.07

Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. J Exp Med (2006) 2.77

Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med (2005) 2.67

Robotic versus laparoscopic hepatectomy: a matched comparison. Ann Surg (2014) 2.58

Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55

The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study. PLoS Med (2014) 2.38

VENO-VENOUS BYPASS WITHOUT SYSTEMIC ANTICOAGULATION IN CANINE AND HUMAN LIVER TRANSPLANTATION. Surg Forum (1983) 2.30

Fatal transfusion-associated graft-versus-host disease in an immunocompetent recipient of a volunteer unit of red cells. Transfusion (2006) 2.26

Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation (2006) 2.24

THE USE OF COMBINED PRESERVATION TECHNIQUES FOR EXTENDED STORAGE OF ORTHOTOPIC LIVER HOMOGRAFTS. Surg Gynecol Obstet (1968) 2.20

Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology (2006) 2.08

A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl (2002) 2.07

Muscle mass predicts outcomes following liver transplantation. Liver Transpl (2013) 2.04

Safety and efficacy of splenic artery embolization for portal hyperperfusion in liver transplant recipients: a 5-year experience. Liver Transpl (2015) 2.03

Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl (2006) 2.02

National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant (2004) 2.01

Role of baseline echocardiography in the preoperative management of liver transplant candidates. Am J Cardiol (2012) 1.98

Near-total human face transplantation for a severely disfigured patient in the USA. Lancet (2009) 1.97

Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg (2005) 1.93

Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology (2004) 1.92

Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis (2003) 1.89

Treatment of hepatic epithelioid hemangioendothelioma: a single-institution experience with 25 cases. Arch Surg (2009) 1.82

Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl (2005) 1.79

The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med (2005) 1.75

Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant (1989) 1.74

Complications of right lobe living donor liver transplantation. J Hepatol (2009) 1.73

First U.S. near-total human face transplantation: a paradigm shift for massive complex injuries. Plast Reconstr Surg (2010) 1.70

In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology (2006) 1.63

Posttransplant biliary complications in the pre- and post-model for end-stage liver disease era. Liver Transpl (2011) 1.63

Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation (2008) 1.62

Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61

A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells. Blood (2011) 1.60

EFFECT OF CYCLOSPORIN ON HEPATIC REGENERATION. Surg Forum (1986) 1.59

Long-term survival, nutritional autonomy, and quality of life after intestinal and multivisceral transplantation. Ann Surg (2012) 1.59

Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant (2003) 1.58

Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.56

Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood (2011) 1.55

ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology (2002) 1.54

Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52

Side-to-side cavocavostomy with an endovascular stapler: Rescue technique for severe hepatic vein and/or inferior vena cava outflow obstruction after liver transplantation using the piggyback technique. Liver Transpl (2009) 1.51

Enhancing alloreactivity does not restore GVHD induction but augments skin graft rejection by CD4⁺ effector memory T cells. Eur J Immunol (2011) 1.49

Safety and effectiveness of renoportal bypass in patients with complete portal vein thrombosis: an analysis of 10 patients. Liver Transpl (2015) 1.49

Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant (2006) 1.48

The innate immune response and activation of coagulation in alpha1,3-galactosyltransferase gene-knockout xenograft recipients. Transplantation (2009) 1.47

Carbon monoxide inhalation protects rat intestinal grafts from ischemia/reperfusion injury. Am J Pathol (2003) 1.47

Functionally important glycosyltransferase gain and loss during catarrhine primate emergence. Proc Natl Acad Sci U S A (2006) 1.46

HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant (2005) 1.46

Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology (2011) 1.44

Transplantation of en bloc pediatric kidneys when the proximal vascular cuff is too short. Transplantation (2007) 1.42

Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2011) 1.40

Three-dimensional print of a liver for preoperative planning in living donor liver transplantation. Liver Transpl (2013) 1.39

Biliverdin protects the functional integrity of a transplanted syngeneic small bowel. Gastroenterology (2004) 1.39

SUCCESSFUL ORTHOTOPIC TRANSPLANTATION OF LIVER HOMOGRAFTS AFTER EIGHT TO TWENTY-FIVE HOURS PRESERVATION. Surg Forum (1967) 1.37

Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr (2006) 1.36

Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. Am J Transplant (2005) 1.36

MELD and prediction of post-liver transplantation survival. Liver Transpl (2006) 1.33